Participated · Equity · May 2026

Tequipy operates a local-first logistics and IT operations network that coordinates hundreds of local partners to source, configure, deliver, service, and retrieve employee devices without central warehousing or cross-border shipping. The company automates hardware-focused global IT operations to replace fragmented manual workflows involving local suppliers, couriers, customs brokers and warehouses. Tequipy serves more than 150 fast-growing tech customers, including Booksy, Connecteam, Gigs, ICEYE, RemoFirst, and Taptap Send, and reported 7x growth in the last year. Having started with hardware because it is the hardest part to automate, the company plans to expand its platform into software and security operations covering accounts, licences, access, and employee lifecycle processes. Its stated goal is to remove around 80% of manual operational work from global IT teams.

Participated · Seed · Apr 2026

Alien develops a decentralized identity L1 network intended to verify humans and link AI agents to their human owners, creating trust and accountability in the agentic economy. The company is releasing and open-sourcing Alien Agent IDs to give agents verifiable credentials tied to real human Alien IDs. Its first demonstrated use case is an Agent ID for Claude Code that attaches a verified badge to every commit to prove human authorization. Alien is led by CEO Kirill Avery and is headquartered in San Francisco. Financially, the company recently closed a $7.1M pre-seed round to fund operations expansion and further product development.

Participated · Series B · Jan 2026

Juvena Therapeutics leverages artificial intelligence and insights from human stem cell biology to engineer first-in-class regenerative biologics aimed at reversing tissue degeneration. Its lead candidate, JUV-161, is in Phase 1 studies and has shown preclinical benefits in myogenesis, muscle metabolism, and strength for myopathic conditions; dosing is complete in five of six SAD cohorts and all MAD cohorts with study completion expected by January. The company recently signed a research and collaboration agreement with Eli Lilly worth more than $650 million in potential milestones, underscoring the commercial interest in its platform. Proceeds from the latest financing will fund advancement of JUV-161, expansion of its pipeline targeting neuromuscular and age-related diseases, and further development of its AI discovery capabilities. Juvena is also pursuing additional partnership opportunities and has launched a search for a new CEO as it scales. Headquartered in Redwood City, California, the company has expanded its board and clinical leadership team to support its next phase of growth. No revenue or user metrics have been disclosed, but the company positions itself as a leader in regenerative medicine.

Participated · Equity · Oct 2025

Sitehop is a Sheffield-based cybersecurity startup that has created the SAFEseries, a hardware platform that performs line-speed, quantum-ready encryption while consuming just one-tenth of the energy of traditional software-based solutions. By embedding encryption directly into hardware, the company eliminates the latency bottlenecks that plague software approaches, making it attractive for data-intensive applications across telecoms, financial services and national infrastructure. Early traction includes a live deployment with a tier-one carrier operating in five countries and a proof-of-concept trial in BT’s Gemini test facility, where Sitehop became the first external company granted access. Founded by telecoms veteran Melissa Chambers and FPGA/cryptography expert Ben Harper, the team positions its technology as future-proof protection against quantum-era threats. The fresh capital will be used to accelerate international expansion while continuing to build UK-sovereign encryption capability. To date, the company has raised £13.5 million, with earlier backing from investors such as Amadeus Capital Partners, Manta Ray, Mercia Ventures and NPIF – Mercia Equity Finance.

Participated · Series A · Oct 2025

Bettani Farms, recently rebranded from Climax Foods, is a Berkeley-based food-technology company focused on creating dairy-free cheeses. Its products—including mozzarella and feta—are built on a proprietary ingredient called Caseed, designed to mimic the functional properties of casein while remaining completely plant-based. The company positions its cheeses as protein-rich and free of common allergens such as nuts and soy. To strengthen execution, Bettani Farms has added industry veterans: former Califia Farms CFO Sandeep Patel now serves as CEO and chairman, while new senior hires span R&D, sales, and process engineering. The fresh leadership aims to accelerate product development and commercialization. Although specific revenue or user metrics were not disclosed, the firm plans to deploy new capital to expand operations and intensify R&D efforts, signaling a focus on scaling production and market reach.